COMMUNIQUÉS West-GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
26/01/2026
Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26/01/2026
WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
26/01/2026
Daix (France), New York City (New York, Etats-Unis), le 26 janvier 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement de thérapies orales pour [...]
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
26/01/2026
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after [...]
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast
26/01/2026
GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Hapbee Appoints Marketing Expert Bally Singh to Board of Directors to Spearhead Global Brand Evolution
26/01/2026
Strategic move aligns with record $6.8 trillion global wellness market surge - forecasted to hit $9.8 trillion by 2029 - and drives major company-wide rebrand VANCOUVER, British Columbia, Jan. 26, 2026 (GLOBE NEWSWIRE [...]
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
26/01/2026
ELPIS II top-line trial results are anticipated in the third quarter of 2026 Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are [...]
Purely Me Skin Tag Remover Product Information Updated as Consumer Interest in At-Home Skin Tag Solutions Grows in 2026
26/01/2026
An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching non-prescription skin tag products New York, NY, Jan. 26, 2026 (GLOBE [...]
DoseSpot's pVerify Achieves Multiple 2025 Recognitions from Gartner Digital Markets' Capterra, Software Advice and GetApp
26/01/2026
BOSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- DoseSpot , which delivers best-in-class e-prescribing, insurance verification and revenue cycle management solutions for healthcare providers, announced today that its pVerify [...]
Health-ISAC 2026 Report Details Rising Cyber Threats Across Health Sector
26/01/2026
Report highlights rising ransomware attacks, third-party vulnerabilities, and evolving social engineering tactics shaping health sector security ORLANDO, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Health-ISAC today [...]
Quantum Brainwave Protocol Product Information Updated as Consumer Interest in Digital Audio Relaxation Programs Grows in 2026
26/01/2026
An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching digital audio relaxation programs New York, NY, Jan. 26, 2026 (GLOBE [...]
Da Vinci 5 Cleared for Cardiac Procedures
26/01/2026
FDA 510(k) clearance expands da Vinci 5 indications to include certain cardiac procedures SUNNYVALE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive [...]
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
26/01/2026
- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 (GLOBE NEWSWIRE [...]
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
26/01/2026
Listing expected to expand market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “ [...]
Genyro Signs Exclusive License for “Sidewinder,” a Breakthrough DNA Construction Technology Featured in Nature
26/01/2026
A major technological advance in DNA writing enables researchers to construct and create in the language of biology SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Genyro Inc., a biotechnology company advancing next- [...]
QHSLab (OTCQB:USAQ) Reports Preliminary Unaudited 2025 Financial Results With Strong Revenue Growth, Expanding Margins, and Significant Debt Reduction
26/01/2026
Revenue increased 25% year over year, gross margins expanded to approximately 67%, and convertible debt was substantially eliminated Improved profitability and early Q-Cog reimbursement activity position the Company for [...]
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
26/01/2026
WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Leios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South Korea
26/01/2026
10XB-101 Being Developed for Focal Fat Reduction and Body Contouring LA JOLLA, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Leios Therapeutics, a clinical-stage biotechnology company focused on innovative aesthetic [...]
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
26/01/2026
CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially insured patients Launch [...]

Pages